The American Academy of Pediatrics has announced its endorsement of the World Health Organization's (WHO) recommendation that thimerosal not be banned from vaccines.
The American Academy of Pediatrics has announced its endorsement of the World Health Organization’s (WHO) recommendation that thimerosal not be banned from vaccines.
The preservative, which contains ethyl mercury, has been used in some vaccines since the 1930s as an antibacterial and antifungal agent, according to a commentary published online December 17 in the organization’s official journal, Pediatrics.
According to the authors, the United Nations Environmental Program (UNEP) is developing an international treaty aimed at eliminating controllable mercury pollution and exposure throughout the world due to well-known toxic effects. As part of the treaty, UNEP is considering recommending the removal of thimerosal.
In the statement, the authors distinguish between toxic methyl mercury and the ethyl mercury in thimerosal. They say that although methyl mercury has demonstrated clear toxic effects, studies over the past 15 years have failed to link the use of ethyl mercury to similar serious neurodevelopmental disorders.
The Academy says the use of thimerosal allows the use of multiuse vials, which would reduce the cost of vaccines; global removal could adversely affect the worldwide vaccine supply.
A WHO Strategic Advisory Group of Experts on Immunization recently recommended that the portion of the UNEP treaty specifying thimerosal be removed, the authors state, adding that they agree.
The authors say they strongly support global immunization efforts. Immunization prevents approximately 2.5 million deaths a year globally, and, if strengthened, could prevent millions more.
“The preponderance of available evidence has failed to demonstrate serious harm associated with thimerosal in vaccines. As such, we extend our strongest support to the recent Strategic Advisory Group of Experts recommendations to retain the use of thimerosal in global vaccine supply,” the authors wrote.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.